Siglec-6/CD327 Fc Chimera Protein, Human
Siglec-6/CD327 Fc Chimera Protein, Human
Product Details
Product Details
Product Specification
| Species | Human |
| Accession | AAH35359.2 |
| Amino Acid Sequence | Gln16-Val320, with C-terminal Human IgG Fc |
| Expression System | HEK293 |
| Molecular Weight | 75-95 kDa(Reducing) |
| Purity | ＞95%, by SDS-PAGE under reducing conditions |
| Endotoxin | <0.1EU/μg |
| Conjugation | Unconjugated |
| Tag | Human Fc Tag |
| Physical Appearance | Lyophilized Powder |
| Storage Buffer | PBS, pH7.4 |
| Reconstitution | Reconstitute at less than 1 mg/mL according to the size in ultrapure water after rapid centrifugation . |
| Stability & Storage | · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles. |
Background
Siglec-6 also called CD327, one of the Sialic acid-binding immunoglobulin-like lectins (Siglecs) and type-1 transmembrane protein. Siglec-6 is predominantly expressed by mast cells, B cells, and a minor AS-type dendritic cell subset. Siglec-6 is an immune-inhibitory CD33-related Siglec and strongly binds to sialylated Tn-structures. As an exception, all Siglecs recognize the carboxyl group of sialic acid, but only Siglec-6 does not require the glycerol side-chain for binding. In cancer, Siglec-6 was recently found to be upregulated in circulating and urinary CD8+ T-cell of non–muscle-invasive bladder cancer patients, wherein a high level of Siglec-6 was associated with advanced bladder cancer. Additionally, Siglec-6 is prevalently expressed on acute myeloid leukemia blasts and transformed B cells in chronic lymphocytic leukemia. As Siglec-6 mRNA and protein are not expressed in hematopoietic stem cells, they are novel targets for CAR-T cell immunotherapy in chronic lymphocytic leukemia.
Picture
Picture
SDS-PAGE
